Current options for injectable contraception in the United States

Seminars in Reproductive Medicine

Volumn 19, Issue 4, 2001, Pages 331-337

  Kaunitz, A M ^a  

^a NONE   (United States)

Author keywords

Depo Provera; Depot medroxyprogesterone acetate; Estradiol cypionate; Injectable contraception; Lunelle; Medroxyprogesterone acetate

Indexed keywords

ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; INJECTABLE CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE ACETATE;

AFFECTIVE NEUROSIS; AMENORRHEA; CANCER RISK; CARDIOVASCULAR DISEASE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; FEMALE; FERTILITY; HORMONAL CONTRACEPTION; HUMAN; MENSTRUAL IRREGULARITY; PATIENT COUNSELING; REVIEW; RISK BENEFIT ANALYSIS; UNITED STATES; WEIGHT GAIN;

CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MEDROXYPROGESTERONE 17-ACETATE; PREGNANCY; RISK FACTORS; UNITED STATES;

EID: 0035672471     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18641     Document Type: Review

References (65)

1. Depo-Provera contraception injection: Product information
2. Pharmacokinetics of depot medroxyprogesterone acetate contraception
3. A guide to interpreting contraceptive efficacy studies
4. Contraceptive failure, method-related discontinuation and resumption of use: Results from the 1995 National Survey of Family Growth
5. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer
6. Risk of endometrial cancer in relation to use of combined oral contraceptives: A practitioner's guide to meta-analysis
7. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate
8. In utero exposure to steroid contraceptives and outcome of pregnancy
9. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: A multinational case-control study
10. Uterine leiomyomata
11. Hormonal manipulation in the treatment of premenstrual syndrome
12. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis
13. Injectable contraception
14. Depo-Provera use in an Australian metropolitan practice
15. Treatment of seizures with medroxyprogesterone acetate: Preliminary report
16. Medroxyprogesterone acetate and homozygous sickle-cell disease
17. A model clinic approach to the reproductive health concerns of the mentally handicapped
18. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: A review
19. Breast cancer and depot-medroxyprogesterone acetate: A multinational study
20. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer
21. Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer
22. Depot medroxyprogesterone acetate contraception: Metabolic parameters and mood changes
23. A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate
24. The effect of medroxyprogesterone acetate on blood pressure
25. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: Results of an international, multicenter, case-control study
26. Spinal bone density in women using depot medroxyprogesterone contraception
27. Bone density in long term users of depot medroxyprogesterone acetate
28. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive
29. Bone mineral density in women using depot medroxyprogesterone acetate for contraception
30. Long-term depot-medroxyprogesterone acetate and bone mineral density
31. Forearm bone density in users of Depo-Provera as a contraceptive method
32. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women
33. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors
34. Bone mineral density during long-term treatment with Norplant implants and depot medroxyprogesterone acetate: A cross-sectional study of Thai women
35. Trabecular bone in long-term depot-medroxyprogesterone acetate users
36. Bone density in women receiving depot medroxyprogesterone acetate for contraception
37. Recovery of bone density in women who stop using medroxyprogesterone acetate
38. Steroid hormone contraception and bone mineral density: A cross-sectional study in an international population
39. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women
40. Injectable contraception: New and existing options
41. Experiences of injectable contraceptive users in an urban setting
42. Long-acting injectable contraception with depot medroxyprogesterone acetate
43. Depot medroxyprogesterone acetate: Patterns of use and reasons for discontinuation
44. Contraceptive use-efficacy studies utilizing medroxy-progesterone acetate administered as an intramuscular injection once every 90 days
45. Depo-Provera associated weight gain in Navaho women
46. Metabolic parameter, bleeding, and weight changes in US women using progestin only contraceptives
47. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives
48. Comparative study of weight change between long-term DMPA and IUD acceptors
49. Depressive symptoms and Depo-Provera
50. Depression in users of depo-medroxyprogesterone acetate
51. Physical findings and symptoms of depot medroxyprogesterone acetate use in adolescent females
52. Depot medroxyprogesterone acetate pioneers: A retrospective study at a North Carolina health department
53. The use of hormonal contraception in women with coexisting medical conditions
54. Lunelle contraception injection: Product information
55. Comparative safety, efficacy, and cycle control of Lunelle™ monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum® 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic)
56. 2 in surgically sterile females
57. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): Assessment of return of ovulation after three monthly injections in surgically sterile females
58. Return of fertility after discontinuation of the once-a-month injectable contraceptive Cyclofem
59. Estimates of human fertility and pregnancy loss
60. Comparative study of the effects of two once-a-month injectable steroidal contraceptives (Mesigyna and Cyclofem) on lipid and lipoprotein metabolism
61. A multicentered phase II comparative clinical trial of Mesigyna, Cyclofem, and injectable No. 1 given by intramuscular injection to Chinese women
62. Once-a-month combined injectable contraceptives
63. Bleeding patterns of women using Lunelle™ monthly contraceptive injections (medroxyprogesterone acetate and estradiol cypionate injectable suspension) compared with those of women using Ortho-Novum® 7/7/7 (norethindrone/ethinyl estradiol triphasic) or other oral contraceptives
64. New once-a-month injectable contraceptives, with particular reference to Cyclofem/Cyclo-Provera
65. The introduction of Cyclofem into family planning programmes: Experience from studies in Indonesia, Jamaica, Mexico, Thailand, and Tunisia